AI assistant
Sending…
Chemomab Therapeutics Ltd. — Director's Dealing 2021
Mar 11, 2021
35107_dirs_2021-03-11_ddea1695-4810-4649-ad19-a99babf3e0dc.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Anchiano Therapeutics Ltd. (ANCN)
CIK: 0001534248
Period of Report: 2020-04-23
Reporting Person: Cohen Neil Harris (Director, interim CEO)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-07-16 | Stock Option (right to buy) | $0.17 | A | 55000 | Acquired | 2030-07-15 | Ordinary Shares (55000) | Direct |
Footnotes
F1: 25% of shares underlying the option vests on July 16, 2021, and 12.5% of the remaining shares underlying the option vest in eight equal quarterly installments thereafter.
More from Chemomab Therapeutics Ltd.
Board/Management Information
2026
Jun 2
Report Publication Announcement
2026
May 14
Regulatory Filings
2026
Mar 19
Regulatory Filings
2025
Nov 21
Capital/Financing Update
2025
Aug 22
Interim / Quarterly Report
2025
Aug 14
Major Shareholding Notification
2025
Aug 11
Capital/Financing Update
2025
Jul 25
Capital/Financing Update
2025
Jul 25
Declaration of Voting Results & Voting Rights Announcements
2025
Jul 1